CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in ...
Imphal Times

Fragment 176-191: A Versatile Molecule in Mammalian Oncology, Skeletal Research, and Beyond

The peptide known as Fragment 176-191 (also sometimes linked with AOD-9604 in its analog forms) is a truncated portion of ...
Open Heart

Beta blockers and hypertrophic obstructive cardiomyopathy: a systematic review and meta-analysis

Background Since the 1960s, beta blockers have been used to treat hypertrophic obstructive cardiomyopathy (HOCM), a genetic ...
Frontiers

Correction: Psychiatric adverse events associated with infliximab: a cohort study from the French nationwide discharge abstract database

Author Grégoire Ficheur was erroneously included as an author in the published article. The correct author list reads: Eve-Marie Thillard, Sophie Gautier, Evgeniya Babykina, Louise Carton, Ali Amad, ...
Frontiers

Investigation and Analysis on the Charging Status and Standard of Pharmacy Intravenous Admixture Service in China

The final, formatted version of the article will be published soon. Objective: The charging policy of pharmacy intravenous admixture services (PIVAS) is not merely a minor "billing issue" confined to ...